4-ethylphenyl-3-chloropropionate | 79780-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-ethylphenyl-3-chloropropionate
• 英文别名: (4-Ethylphenyl) 3-chloropropanoate
• CAS: 79780-67-9
• 化学式: C₁₁H₁₃ClO₂
• 分子量: 212.676
• InChiKey: QPRJCNLSGYIFKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-ethylphenyl-3-chloropropionate 在 aluminum (III) chloride 、 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 4-ethyl-7-hydroxy-1-indanone
  参考文献：
  名称：

  Discovery of potent and orally active tricyclic-based FBPase inhibitors

  摘要：

  With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discovery of prodrug 15c, which strongly inhibited glucose production in monkey hepatocytes. Furthermore, prodrug 15c lowered blood glucose levels in fasted cynomolgus monkeys. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.041
• 作为产物：
  描述：

  3-氯丙酰氯 生成 4-ethylphenyl-3-chloropropionate
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• ——
  作者：

  DOI：——

  日期：——
• Discovery of potent and orally active tricyclic-based FBPase inhibitors
  作者：Tomoharu Tsukada、Osamu Kanno、Takahiro Yamane、Jun Tanaka、Taishi Yoshida、Akira Okuno、Takeshi Shiiki、Mizuki Takahashi、Takahide Nishi

  DOI：10.1016/j.bmc.2010.05.041

  日期：2010.7

  With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discovery of prodrug 15c, which strongly inhibited glucose production in monkey hepatocytes. Furthermore, prodrug 15c lowered blood glucose levels in fasted cynomolgus monkeys. (C) 2010 Elsevier Ltd. All rights reserved.
• Alkanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0003664B1

  公开（公告）日：1982-02-17
• US4275058A
  申请人：——

  公开号：US4275058A

  公开（公告）日：1981-06-23
• Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors
  作者：Tomoharu Tsukada、Mizuki Takahashi、Toshiyasu Takemoto、Osamu Kanno、Takahiro Yamane、Sayako Kawamura、Takahide Nishi

  DOI：10.1016/j.bmcl.2009.12.056

  日期：2010.2

  With the goal of improving metabolic stability and further enhancing FBPase inhibitory activity, a series of tricyclic 8H-indeno[1,2-d][1,3]thiazoles was designed and synthesized with the aid of structure-based drug design. Extensive SAR studies led to the discovery of 19a with an IC50 value of 1 nM against human FBPase. X-ray crystallographic studies revealed that high affinity of 19a was due to the hydrophobic interaction arising from better shape complementarity and to the hydrogen bonding network involving the side chain on the tricyclic scaffold. (c) 2010 Elsevier Ltd. All rights reserved.